Keyword: MedImmune Ventures
Mohammed Dar lines up as the latest AstraZeneca/MedImmune executive to jump ship into U.K. biotech Immunocore.
Bloomberg reports that Sean Bohen, CMO and EVP of global medicines development, is out the door at AstraZeneca.
Nearly a year after its former chief Eliot Forster stepped down, Immunocore has a new full-time CEO in Medimmune’s president Bahija Jallal.
FDA review division director Badrul Chowdhury moved to AstraZeneca, the latest in a string of jumps to the pharmaceutical industry within the past year.
Pandion Therapeutics is working on localized treatments for autoimmune and inflammatory disease.
After a failed trial in May, AstraZeneca hoped tralokinumab could pass subpopulation tests and make it to the finish line, but it wasn’t meant to be.
AstraZeneca and MedImmune have hired a clutch of new cancer R&D execs.
AstraZeneca had a pretty rough few years of R&D setbacks and failures up until 2012, when its former chief, David Brennan, was all but pushed out as a result. But things seem to have steadied somewhat since Pascal Soriot took the helm.
AstraZeneca’s biologics arm MedImmune and synthetic biology co Abpro have joined forces on a new Ang2-VEGF research collab that will come together under a new spinout.